Lyell Immunopharma Q2 EPS $(2.89) Beats $(3.82) Estimate, Sales $8.000K Down From $13.000K YoY
Lyell Immunopharma (NASDAQ:LYEL) reported quarterly losses of $(2.89) per share which beat the analyst consensus estimate of $(3.82) by 24.4 percent. This is a 19.5 percent increase over losses of $(3.59) per share from